Patents by Inventor Heidi Rommelaere

Heidi Rommelaere has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-?
    Patent number: 11897951
    Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-? and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: February 13, 2024
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Nadine Biesemann, Ann Brigé, Sigrid Cornelis, Karen Heyninck, Eric Lorent, Shanna Van Zwam
  • Methods of treating asthma with polypeptides targeting IL-13 and TSLP
    Patent number: 11840566
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: December 12, 2023
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same
    Patent number: 11773159
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: October 3, 2023
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND IL-23
    Publication number: 20220372128
    Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: April 25, 2022
    Publication date: November 24, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND IL-23
    Publication number: 20220363747
    Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: April 25, 2022
    Publication date: November 17, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF-a
    Publication number: 20220356241
    Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-? and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 17, 2021
    Publication date: November 10, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Nadine Biesemann, Ann Brigé, Sigrid Cornelis, Karen Heyninck, Eric Lorent, Shanna Van Zwam
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20220195031
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: February 24, 2022
    Publication date: June 23, 2022
    Applicant: Merck Patent GmbH
    Inventors: Heidi ROMMELAERE, Joost Alexander KOLKMAN, Michael John Scott SAUNDERS, Ann UNION, Yolande CHVATCHKO, Amanda E.I. PROUDFOOT, Alain VICARI, Denis BRUNIQUEL, Laurent CHEVALET, Olivier LEGER
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20220177564
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20220177565
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20220177566
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND OX40L
    Publication number: 20220153854
    Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISV binds to OX40L and at least two ISVDs bind to IL-13. The present disclosure also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: September 24, 2021
    Publication date: May 19, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Klaus Erb, Eric Lorent, John Park, Robert Resnick, Melanie Rieger, Bernd Weigle
  • Polypeptides comprising immunoglobulin single variable domains targeting TNFA and IL-23
    Patent number: 11332525
    Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: May 17, 2022
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND IL-23
    Publication number: 20220064281
    Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: October 15, 2021
    Publication date: March 3, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
  • Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
    Patent number: 11208476
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: December 28, 2021
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20210214431
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: March 22, 2021
    Publication date: July 15, 2021
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernhard Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20210188965
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 24, 2021
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND IL-23
    Publication number: 20210188963
    Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 24, 2021
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND OX40L
    Publication number: 20210188986
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an autoimmune or inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to TNF? and at least two ISVDs binds to OX4OL. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 24, 2021
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Peter Florian, Karen Heyninck, Thomas Kreutzberg, Thomas Leeuw, Eric Lorent, Oezen Sercan Alp, Gertrud Sibenhorn
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20210130452
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: September 29, 2020
    Publication date: May 6, 2021
    Applicant: Merck Patent GmbH
    Inventors: Heidi ROMMELAERE, Joost Alexander KOLKMAN, Michael John Scott SAUNDERS, Ann UNION, Yolande CHVATCHKO, Amanda E.I. PROUDFOOT, Alain VICARI, Denis BRUNIQUEL, Laurent CHEVALET, Olivier LEGER
  • Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same
    Patent number: 10829552
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 10, 2020
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger